Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss
Research Associate Professor Marta Scatena and a team of collaborators show that raising Sphingosine-1-phosphate (S1P) levels in adult mice through conditionally deleting or pharmacologically inhibiting S1P lyase, the sole enzyme responsible for irreversibly degrading S1P, markedly increased bone formation, mass and strength and substantially decreased white adipose tissue.
